<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="117597">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01816269</url>
  </required_header>
  <id_info>
    <org_study_id>cu1959</org_study_id>
    <nct_id>NCT01816269</nct_id>
  </id_info>
  <brief_title>Effect of Dental Scaling on Helicobacter Pylori Eradication and Reinfection</brief_title>
  <acronym>Scaling and Hp</acronym>
  <official_title>Effect of Dental Scaling on Helicobacter Pylori Eradication and Reinfection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Goztepe Training and Research Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Goztepe Training and Research Hospital</source>
  <oversight_info>
    <authority>Turkey: Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients who had received H.pylori eradication treatment will be categorised as eradication
      and reinfection status and whether dental scaling has any influence on these results.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients over 18 years with no comorbidities especially liver, cardiac and haemorrhagic
      diathesis and giving informed consent will be categorised according to their status of
      dental scaling,  eradication and reinfection rates of h.pylori.

      Statistical examination will include the multiple regression and Chi-Square.

      The result will emphasize the influence of dental scaling on eradication (Presence of Hp
      cure 1-6 months after treatment) and reinfection ( reappearance of Hp 12 months later than
      the treatment).
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Anticipated">May 2013</completion_date>
  <primary_completion_date type="Anticipated">May 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Retrospective</study_design>
  <primary_outcome>
    <measure>The eradication and reinfection rates in dental scaled and non-scaled patients.</measure>
    <time_frame>last 1 year</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reinfection rate of patients treated for H.pylori</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Helicobacter Pylori Infection</condition>
  <arm_group>
    <arm_group_label>Patients with scaling and patients without scaling</arm_group_label>
    <description>No drug</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Helicobacter eradicated or non-eradicated</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Eligible population with H.pylori infection and result of treatment based on presence of
        dental scaling.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients over 18 with h.pylori positivity and received anti-Hp treatment giving
             informed consent to analyse of their data on this subject.

        Exclusion Criteria:

          -  Comorbidities with cardiac, liver and medical contraindication to perform dental
             scaling.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>GoztepeTRH</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GoztepeTRH</name>
      <address>
        <city>Istanbul</city>
        <zip>34727</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <lastchanged_date>March 21, 2013</lastchanged_date>
  <firstreceived_date>March 20, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Goztepe Training and Research Hospital</investigator_affiliation>
    <investigator_full_name>Celal Ulasoglu</investigator_full_name>
    <investigator_title>MD Department of Gastroenterology</investigator_title>
  </responsible_party>
  <keyword>Helicobacter pylori</keyword>
  <keyword>Dental scaling</keyword>
  <keyword>Eradication</keyword>
  <keyword>Reinfection</keyword>
  <keyword>Helicobacter status</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Helicobacter Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
